Key Points
- COO Cortney Caudill sold 4,263 shares on Nov. 1 at an average price of $65.19 for about $277,905, cutting her stake by 25.08% to 12,737 shares, according to an SEC filing.
- Strong quarterly results: Halozyme reported Q results on Nov. 3 with EPS of $1.72 (vs. $1.63 est.) and revenue of $354.3M (vs. $339.2M), a 22.1% YoY revenue increase and a net margin of 47.91%.
- Analysts hold a consensus "Hold" rating with an average price target of $75.10; the company has a market cap of about $7.92B and a P/E of 14.18.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) COO Cortney Caudill sold 4,263 shares of the company's stock in a transaction dated Saturday, November 1st. The stock was sold at an average price of $65.19, for a total transaction of $277,904.97. Following the completion of the transaction, the chief operating officer owned 12,737 shares in the company, valued at approximately $830,325.03. The trade was a 25.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Halozyme Therapeutics Price Performance
Shares of HALO stock opened at $67.35 on Friday. The company's 50-day simple moving average is $67.14 and its two-hundred day simple moving average is $64.90. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37. Halozyme Therapeutics, Inc. has a one year low of $46.26 and a one year high of $79.50. The company has a market capitalization of $7.92 billion, a P/E ratio of 14.18, a P/E/G ratio of 0.35 and a beta of 0.95.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.63 by $0.09. The company had revenue of $354.26 million for the quarter, compared to analysts' expectations of $339.18 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.Halozyme Therapeutics's revenue was up 22.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.27 earnings per share. As a group, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.
Institutional Investors Weigh In On Halozyme Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Lindenwold Advisors INC grew its holdings in Halozyme Therapeutics by 2.5% in the third quarter. Lindenwold Advisors INC now owns 8,221 shares of the biopharmaceutical company's stock worth $603,000 after purchasing an additional 201 shares during the last quarter. Allworth Financial LP grew its stake in Halozyme Therapeutics by 322.5% during the 3rd quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company's stock valued at $2,914,000 after purchasing an additional 30,331 shares during the last quarter. IFP Advisors Inc increased its holdings in shares of Halozyme Therapeutics by 17.8% in the third quarter. IFP Advisors Inc now owns 5,206 shares of the biopharmaceutical company's stock valued at $382,000 after purchasing an additional 785 shares during the period. Swiss Life Asset Management Ltd purchased a new position in shares of Halozyme Therapeutics in the third quarter worth about $426,000. Finally, CIBC Private Wealth Group LLC raised its stake in shares of Halozyme Therapeutics by 12.8% in the third quarter. CIBC Private Wealth Group LLC now owns 2,891 shares of the biopharmaceutical company's stock worth $212,000 after purchasing an additional 329 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on HALO. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Friday. Citigroup restated a "market outperform" rating on shares of Halozyme Therapeutics in a report on Tuesday, November 4th. Leerink Partners raised shares of Halozyme Therapeutics from an "underperform" rating to a "market perform" rating and set a $70.00 price target for the company in a research report on Tuesday, October 14th. Leerink Partnrs raised shares of Halozyme Therapeutics from a "strong sell" rating to a "hold" rating in a report on Tuesday, October 14th. Finally, Morgan Stanley reduced their price objective on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an "overweight" rating for the company in a research note on Monday, October 20th. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $75.10.
Get Our Latest Analysis on HALO
Halozyme Therapeutics Company Profile
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
